Rizatriptan

What it is

Rizatriptan is a synthetic small molecule, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine, sold as the benzoate salt. It is one of the triptans, a class of selective serotonin 5-HT1B/1D receptor agonists developed for migraine attacks. It comes as a swallowed tablet, an orally disintegrating tablet and an oral film, and it is a prescription medicine in the United States. It is not a nutrient and nothing in the diet contains it.

What the research says

The evidence is that rizatriptan shortens an individual migraine attack; it does not prevent migraine. In pooled randomised trials, standard-dose triptans leave roughly 42 to 76 percent of people with headache relief at two hours and 18 to 50 percent pain free, against substantial placebo responses, and rizatriptan 10 mg sits at the more effective end of the class. It does not work for every migraine-like condition: a randomised trial in vestibular migraine found no benefit at one hour. Its own harms are mostly short-lived (dizziness, somnolence, fatigue, chest or neck pressure), but repeated use for 10 or more days a month is linked to medication overuse headache, and withdrawal of the overused drug is itself associated with a transient worsening of headache.

Evidence grade: Well established.

How it works

Drug class: Selective serotonin 5-HT1B/1D receptor agonist (triptan)

Rizatriptan sticks tightly to 5-HT1B and 5-HT1D serotonin receptors on blood vessels inside the skull and on the sensory nerves of the trigeminal system. Binding there is believed to narrow dilated intracranial vessels and damp down the release of pain-signalling peptides from those nerves, which is how it is thought to stop an attack rather than prevent one. It is broken down mainly by the enzyme monoamine oxidase-A, not by the liver's CYP enzymes. (Source 1)

What it is used for

• Randomised trials and network meta-analyses consistently show rizatriptan 10 mg beats placebo for pain relief and pain freedom at two hours, and it is among the more effective oral triptans. The absolute response is partial: in pooled trial data roughly four to seven people in ten get headache relief at two hours, and fewer become completely pain free. Evidence: established. (Source 2)
• One large adaptive-enrichment randomised trial found 30.6 percent pain free at two hours on rizatriptan versus 22.0 percent on placebo in 12 to 17 year olds, an absolute difference of about 9 percentage points. A 2026 network meta-analysis of paediatric acute migraine drugs put rizatriptan at the lowest odds ratio of the agents that reached significance. Evidence: limited. (Source 3)
• Two identical randomised placebo-controlled trials in 707 women using the ICHD-II menstrual migraine definition found 2-hour pain relief in 70 and 73 percent on rizatriptan 10 mg versus 53 and 50 percent on placebo. A 2025 Bayesian network meta-analysis confirmed a benefit over placebo but also found more adverse events than placebo. Evidence: established. (Source 4)
• A double-blind randomised trial of 240 moderate or severe attacks found rizatriptan no different from placebo for reducing vertigo or unsteadiness at one hour, and the authors stated the findings do not support this use. Evidence: not-supported. (Source 5)
• Rizatriptan is an attack treatment, not a preventive. The label states that the safety of treating on average more than four headaches in a 30-day period has not been established, and frequent use of acute migraine drugs is itself a cause of medication overuse headache. The supporting review of medication overuse headache is a narrative review rather than a systematic review or meta-analysis. Evidence: unknown. (Source 6)

Interactions

• Propranolol (pharmacokinetic study): Propranolol blocks the MAO-A enzyme that clears rizatriptan, so blood levels rise by roughly two thirds. The regulator's response is to cap the dose at 5 mg in adults taking propranolol. Nadolol and metoprolol did not do this. (Source 7)
• Propranolol (regulator's dosing response) (label): The label records the interaction as a 70 percent rise in rizatriptan exposure and tells prescribers to adjust the dose. (Source 8)
• Monoamine oxidase inhibitors (including MAO-A inhibitors such as moclobemide, and non-selective MAOIs) (label): Because MAO-A is the main route of breakdown, an MAO inhibitor raises rizatriptan levels. The label makes this a contraindication, including for two weeks after stopping the MAOI. (Source 8)
• SSRI and SNRI antidepressants (case reports): Both raise serotonin signalling, and serotonin syndrome has been reported with the combination. The best quantification available puts the risk very low: about 0.6 definite cases per 10,000 person-years of co-prescription. (Source 9)
• Ergotamine and ergot-type drugs (dihydroergotamine, methysergide) (label): Both constrict blood vessels, so the effects can add up. Use within 24 hours of each other is contraindicated. (Source 8)
• Other triptans and 5-HT1 agonists (label): Taking another triptan within 24 hours is contraindicated because the vessel-narrowing effects may be additive. (Source 8)
• Food in general (a meal taken with the tablet) (pharmacokinetic study): Food does not change how much rizatriptan gets into the blood, but it pushes the peak back by about an hour, which matters for a drug taken to stop an attack quickly. (Source 1)
• Grapefruit and CYP-active herbs such as St John's wort (as a pharmacokinetic interaction) (theoretical): Rizatriptan is cleared mainly by monoamine oxidase-A rather than the CYP3A4 enzyme that grapefruit juice and St John's wort act on, so a grapefruit-type pharmacokinetic interaction is not expected. Neither grapefruit nor St John's wort appears in the label's interaction section. St John's wort is serotonergic, so a serotonin-syndrome concern is theoretical by analogy with SSRIs and SNRIs rather than documented; we found no human study of the pair. (Source 10)
• Alcohol (label): No alcohol interaction is documented. The label's complete drug interaction section covers only propranolol, ergot drugs, other 5-HT1 agonists, SSRIs and SNRIs, and MAO inhibitors, and we found no human study of rizatriptan with alcohol. Alcohol is separately a common migraine trigger, which is a different matter from a drug interaction. (Source 8)
• Aspartame (phenylalanine) in the orally disintegrating tablet (label): The orally disintegrating form contains phenylalanine, which matters to people with phenylketonuria who must limit it. The plain swallowed tablet is a different formulation. (Source 11)

Stopping it

• Rizatriptan is taken attack by attack, not continuously, so there is no taper. The regulator's position is that overusing acute migraine drugs on 10 or more days a month can turn migraine into medication overuse headache, and that coming off the overused drug commonly brings a temporary worsening of headache that may itself need treatment. (Source 12)
• A 2026 narrative review of medication overuse headache, which reports no effect sizes, states that the brain changes seen in the condition appear largely reversible after successful withdrawal plus preventive treatment, and that behavioural features such as craving and impulsivity help keep the overuse going. (Source 13)
• The same narrative review states that withdrawal is still central to treatment, but that preventives, especially CGRP-targeting antibodies and gepants, can now be started before or alongside withdrawal rather than after it. (Source 13)
• The label's own limit on how often it should be used is a position rather than a trial result: the safety of treating more than about four headaches in 30 days has not been established. (Source 6)

What goes wrong

Pooled single-dose trial data reported in the label show dose-related adverse reactions against placebo, with dizziness 9 percent and asthenia or fatigue 7 percent on rizatriptan 10 mg versus 5 and 2 percent on placebo. (Source 14)

• Official position, Moderate certainty.
• Size: rizatriptan 5 mg N=977, rizatriptan 10 mg N=1167, placebo N=627.
• Who: adults in the single-dose controlled trials summarised by the regulator.
• How long: single dose.
• Result: 10 mg versus placebo: dizziness 9% vs 5%, somnolence 8% vs 4%, asthenia/fatigue 7% vs 2%, nausea 6% vs 4%, chest tightness/pressure/heaviness 3% vs 1%, neck/throat/jaw pain or tightness 2% vs 1%, paraesthesia 4% vs <2%.
• Funding: manufacturer-submitted trial data as summarised by the US regulator; this is the label's position, dated February 2026.

Adverse Reactions MAXALT 5 mg (N=977) MAXALT 10 mg (N=1167) Placebo (N=627)

In a 12-month open-label safety study of intermittent rizatriptan in adolescents, 66.0 percent had at least one adverse event and 2.6 percent had a serious adverse event. (Source 15)

• Cohort study, Low certainty.
• Size: 674 enrolled, 606 treated (583 on 10 mg, 23 on 5 mg)
• Who: paediatric migraineurs aged 12-17 treating up to 8 attacks a month.
• How long: mean 292 days in study, mean 20 doses taken.
• Result: 66.0% (400/606) any adverse event, 23.4% (142) a triptan-related adverse event, 2.3% (14) discontinued for an adverse event, 2.6% (16) a serious adverse event; 3 serious events judged drug-related, all classed serious only because they involved more than one dose in 24 hours.
• Funding: not stated in the abstract; single-arm open-label manufacturer study, no comparator.

66.0% (400) of the 606 treated patients had any adverse event, 2.3% (14) discontinued due to an adverse event, 2.6% (16) had a serious adverse event, and 23.4% (142) had a triptan-related adverse event

A network meta-analysis of menstrual migraine trials found adverse events significantly more likely with rizatriptan than placebo. (Source 16)

• Meta-analysis, Low certainty.
• Size: randomised controlled trials to December 2023 in a Bayesian network.
• Who: women treating menstrual migraine attacks.
• How long: single attacks.
• Result: Adverse events rizatriptan versus placebo OR 2.7 (95% CI 1.1-7.3); sustained freedom from pain versus placebo OR 1.9 (1.2-3.3)
• Funding: not stated in the abstract; the review notes a lack of safety analysis for the comparator lasmiditan.

Limit of this finding: The interval on this estimate is wide (odds ratio 2.7, 95% confidence interval 1.1 to 7.3), so it shows adverse events were more common than with placebo but does not pin down how much more. The review also states it could not analyse safety for lasmiditan, so this is not a like-for-like safety ranking across the drugs it compared.

Regarding safety, the probability of adverse events was significantly higher for rizatriptan (OR, 2.7; 95% CI 1.1-7.3) than for placebo.

Two case reports describe renal infarction after therapeutic doses of rizatriptan or zolmitriptan, attributed to peripheral vasospasm. (Source 17)

• Case report, Very low certainty.
• Size: 2 patients.
• Who: a 57-year-old man with hypertension and cluster headache given two therapeutic rizatriptan doses, and a 34-year-old man on zolmitriptan.
• How long: within days of dosing.
• Result: CT and renal arteriography confirmed wedge-shaped renal infarction in both; the authors state triptans may induce peripheral vasospasm leading to renal infarction.
• Funding: not stated.

Limit of this finding: Two case reports cannot establish how often this happens, and the paper itself says triptan-induced vasoconstriction has only rarely been reported to cause events of this kind. The vasospasm explanation is the authors' interpretation of two patients, not a measured mechanism, and one of the two cases involved zolmitriptan rather than rizatriptan.

Triptan-induced vasoconstriction is attributed to its activity on peripheral 5-HT1B receptors and has rarely been reported to result in stroke, myocardial infarction and ischemic colitis.

What the evidence supports

In a meta-analysis of 53 randomised trials of oral triptans, rizatriptan 10 mg had better efficacy and consistency than the sumatriptan 100 mg reference with similar tolerability. (Source 2)

• Meta-analysis, Moderate certainty.
• Size: 24,089 patients across 53 trials (12 unpublished)
• Who: adults treating a migraine attack of moderate or severe intensity.
• How long: single attack, outcomes to 24 hours.
• Result: Reference arm sumatriptan 100 mg: 59% (95% CI 57-60) 2 h headache response, 29% (27-30) 2 h pain free, 20% (18-21) sustained pain free; rizatriptan 10 mg better on efficacy and consistency. Placebo-subtracted proportion with at least one adverse event 13% (8-18) for the reference arm.
• Funding: industry data: raw patient data requested from and supplied by the pharmaceutical companies.

Compared with these data, 10 mg rizatriptan showed better efficacy and consistency, and similar tolerability

A network meta-analysis of 133 randomised trials put the absolute two-hour response to standard-dose triptans at 42 to 76 percent, with rizatriptan orally disintegrating tablets among the most favourable. (Source 18)

• Systematic review, Moderate certainty.
• Size: 133 randomised controlled trials.
• Who: adults with acute migraine.
• How long: single attack, outcomes to 24 hours.
• Result: 2 h headache relief 42-76%; 2 h sustained freedom from pain 18-50%; sustained relief at 24 h 29-50%; rescue medication use 20-34%.
• Funding: not stated in the abstract.

Standard dose triptans relieved headaches within 2 hours in 42 to 76% of patients, and 2-hour sustained freedom from pain was achieved for 18 to 50% of patients.

In a randomised placebo-controlled trial in 12 to 17 year olds, rizatriptan produced pain freedom at two hours in 30.6 percent versus 22.0 percent on placebo. (Source 3)

• Randomized trial, Moderate certainty.
• Size: 570 adolescents analysed for the primary endpoint (284 rizatriptan, 286 placebo)
• Who: migraineurs aged 12-17 with an unsatisfactory response to NSAIDs or paracetamol.
• How long: single attack.
• Result: 87/284 (30.6%) versus 63/286 (22.0%), odds ratio 1.55 (95% CI 1.06 to 2.26), p = 0.025; absolute difference about 8.6 percentage points, which is about 12 children treated for one extra pain-free result.
• Funding: not stated in the abstract; trial used a sponsor-designed adaptive enrichment design (NCT01001234)

A higher proportion of 12-17-year-olds on rizatriptan had pain freedom at 2 hours compared with those on placebo: 87/284 (30.6%) versus 63/286 (22.0%), odds ratio = 1.55 [95% CI: 1.06 to 2.26], p = 0.025.

Two randomised placebo-controlled trials in women with ICHD-II menstrual migraine found 2-hour pain relief in 70 and 73 percent on rizatriptan versus 53 and 50 percent on placebo. (Source 4)

• Randomized trial, Moderate certainty.
• Size: 707 women (MM1 357, MM2 350)
• Who: adult women meeting the ICHD-II definition of menstrual migraine, treating one attack of moderate or severe pain.
• How long: single attack with 24-hour follow-up.
• Result: 2 h pain relief MM1 70% vs 53%, MM2 73% vs 50% (absolute differences of 17 and 23 percentage points); 24 h sustained pain relief 46% vs 33% in both trials.
• Funding: not stated in the abstract.

The percentage of patients reporting 2-h pain relief was significantly greater for rizatriptan than for placebo (MM1 70% vs. 53%, MM2 73% vs. 50%)

What the evidence does not support

A randomised double-blind trial found rizatriptan no better than placebo at one hour for vestibular migraine attacks. (Source 5)

• Randomized trial, Moderate certainty.
• Size: 222 randomised, 134 with active illness treating 307 attacks; 240 attacks analysed for efficacy.
• Who: adults with vestibular migraine at two tertiary neurotology centres.
• How long: up to 3 attacks per participant, outcomes at 1, 24 and 48 hours.
• Result: Vertigo reduced in 73/151 (48.3%) rizatriptan attacks versus 50/88 (56.8%) placebo attacks, OR 0.71 (95% CI 0.42-1.21); unsteadiness/dizziness 29/151 (19.2%) versus 11/89 (12.4%), OR 1.69 (0.80-3.57); rescue remedies added by 26.4% in both groups.
• Funding: not stated in the abstract (NCT02447991)

At 1 hour, rizatriptan did not differ from placebo for reducing vertigo (73/151 [48.3%] vs 50/88 [56.8%] attacks; odds ratio [OR], 0.71 [95% CI, 0.42-1.21])

In a randomised placebo-controlled trial, rizatriptan beat ibuprofen and placebo at two hours but not at 24 hours. (Source 19)

• Randomized trial, Low certainty.
• Size: 155 patients (rizatriptan 53, ibuprofen 52, placebo 50)
• Who: migraine patients with fewer than 8 attacks per month at a tertiary teaching hospital.
• How long: single attack, outcomes at 2 and 24 hours.
• Result: 2 h headache relief 73% rizatriptan, 53.8% ibuprofen, 8% placebo; headache freedom 37.7%, 30.8%, 2%; no advantage at 24 hours; side effects in 9 versus 8 versus 3 patients, non-significant.
• Funding: not stated in the abstract; single-centre, small.

Limit of this finding: This is a single-centre trial of 155 patients, so it is one study rather than a body of evidence. Its own result is split in two: rizatriptan beat both ibuprofen and placebo at two hours, and that advantage had gone by 24 hours.

Rizatriptan was superior to ibuprofen and placebo in relieving headache at 2 h but not at 24 h.

In a 14-year electronic health record study, serotonin syndrome in people co-prescribed a triptan and an SSRI or SNRI was very rare, at 0.6 definite cases per 10,000 person-years. (Source 9)

• Cohort study, Low certainty.
• Size: 47,968 (+/-3) patients prescribed triptans; 19,017 (+/-3) co-prescribed triptans and antidepressants, 30,928 person-years of exposure.
• Who: patients in the Partners Research Data Registry, Greater Boston, 2001-2014.
• How long: 14 years.
• Result: 17 suspected cases, 2 definite (incidence 0.6 per 10,000 person-years, 95% CI 0.0-1.5); adding 5 possible cases gives 2.3 per 10,000 person-years (95% CI 0.6-3.9)
• Funding: not stated in the abstract; retrospective record review, so cases could be missed.

Limit of this finding: The patient counts in this study carry a (+/-3) tolerance, which is the research registry's own de-identification rounding rather than a typographical error. It does not change the incidence figures, which are the point of the finding.

Only 2 patients were classified as having definite serotonin syndrome (incidence rate, 0.6 cases per 10 000 person-years of exposure; 95% CI, 0.0-1.5).

Where the evidence is mixed

In a 2026 network meta-analysis of paediatric acute migraine treatments, rizatriptan had the smallest significant effect of the active drugs, and no drug reduced rescue medication use between two and 24 hours. (Source 20)

• Meta-analysis, Low certainty.
• Size: 30 studies, 8,914 participants, 13 interventions.
• Who: children and adolescents with migraine.
• How long: single attack, outcomes to 24 hours.
• Result: Pain freedom at 2 h versus placebo: sumatriptan/naproxen OR 2.91 (95% CI 1.87-4.53), ibuprofen OR 2.88 (1.47-5.64), rizatriptan OR 1.51 (1.23-1.86)
• Funding: not stated in the abstract.

Limit of this finding: The ranking needs reading carefully. Rizatriptan's odds ratio of 1.51 was the lowest among the drugs that reached statistical significance, not the lowest in the analysis. Dihydroergotamine produced the highest odds ratios but its confidence interval included no effect, so it was not statistically significant. Coming last among the drugs that worked is not the same as not working.

and rizatriptan showed the lowest (OR: 1.51, 95% CI: 1.23-1.86)

A systematic review of observational studies did not find a clear increase in serious ischaemic cardiovascular events with triptans, although stroke findings conflicted. (Source 21)

• Systematic review, Very low certainty.
• Size: 4 studies from 3,370 citations (3 nested case-control, 1 retrospective cohort)
• Who: people with a migraine diagnosis exposed to triptans or ergotamines, compared with unexposed migraineurs.
• How long: database follow-up to December 2013.
• Result: Intensity of use, serious ischaemic events: ergotamines pooled OR 2.28 (95% CI 1.18-4.41), triptans pooled OR 0.86 (95% CI 0.52-1.43, I2 24.5%). Recent triptan use and stroke: OR 0.90 (0.64-1.26) in one study and 2.51 (1.10-5.71) in another, not pooled for heterogeneity.
• Funding: not stated in the abstract; the authors warn that residual uncontrolled confounding reduces confidence in the estimates.

whereas for triptans (three studies) it was 0.86 (95% CI 0.52-1.43; I (2 )= 24.5%)

Where the research disagrees

Whether the 2006 FDA advisory on serotonin syndrome from triptans combined with SSRIs or SNRIs is justified

• US Food and Drug Administration (2006 advisory) and the current US label (February 2026), position, based on spontaneous post-marketing case reports: Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors (Source 12)
• Orlova and colleagues, JAMA Neurology 2018, cohort study of 14 years of electronic health records, 30,928 person-years of co-prescription: Our results cast doubt on the validity of the FDA advisory and suggest that it should be reconsidered. (Source 9)

Whether triptans carry a meaningful risk of serious vascular events in practice

• US label (February 2026), position, based on case reports and class pharmacology; underpins the contraindications: There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of MAXALT. (Source 22)
• Roberto and colleagues, Cephalalgia 2015, systematic review of four observational studies in migraineurs: As for triptans, available studies do not suggest strong CV safety issues, although no firm conclusions can be drawn. In particular, evidence on stroke risk is conflicting. (Source 21)

How much

• Reference intake: There is no dietary reference intake for rizatriptan: it is a prescription drug and the dose is set by the prescriber. As a position dated February 2026, the US label states a starting dose of 5 mg or 10 mg in adults, and a weight-based dose in children aged 6 to 17. (Source 6)
• Upper limit: No upper intake level exists in the nutrition sense. As a regulatory position dated February 2026, the US label caps the adult daily dose at 30 mg in 24 hours, and states that the safety of treating more than four headaches in a 30-day period on average has not been established. (Source 6)
• Studied: The pooled oral triptan meta-analysis analysed rizatriptan at the marketed 5 mg and 10 mg doses alongside other triptans. (Source 2)
• Studied: The paediatric trial gave weight-based dosing: 5 mg for children under 40 kg and 10 mg for those 40 kg or more. (Source 3)
• Studied: The two menstrual migraine trials gave a single rizatriptan 10 mg tablet for one attack. (Source 4)
• Studied: A review of self-medication evidence states the lowest approved dose, 5 mg, was investigated in three randomised controlled trials with 752 patients. (Source 23)

A common belief, and what the research shows

The belief: Triptans like rizatriptan are dangerous for the heart and cause strokes, so they should be avoided by anyone worried about their circulation.

What the research shows: The label does carry vascular contraindications and reports rare serious cardiac events, and the drug is contraindicated in ischaemic coronary disease, prior stroke or TIA, peripheral vascular disease and uncontrolled hypertension. But the observational literature comparing exposed with unexposed migraineurs does not show a clear excess of serious ischaemic events with triptans: the pooled odds ratio for intensity of triptan use was 0.86 (95% CI 0.52-1.43), while for ergotamines it was 2.28 (1.18-4.41). The review's own words are that "available studies do not suggest strong CV safety issues, although no firm conclusions can be drawn. In particular, evidence on stroke risk is conflicting." The honest position is uncertainty concentrated in people who already have vascular disease, not a demonstrated population-wide hazard.

Questions and answers

What is it?

Rizatriptan is a man-made molecule, not a nutrient or a microbe. Chemically it is an indole derivative sold as rizatriptan benzoate, a white to off-white crystalline solid, and it belongs to the triptan family of selective serotonin 5-HT1B/1D receptor agonists. It is supplied as a swallowed tablet, an orally disintegrating tablet and an oral film, in 5 mg and 10 mg strengths. (Source 24)

What does it do in the body?

It binds tightly to 5-HT1B and 5-HT1D serotonin receptors on blood vessels inside the skull and on the sensory nerves of the trigeminal system. That is thought to narrow dilated intracranial vessels and quieten the pain signalling of an attack in progress. It is cleared mainly by the enzyme monoamine oxidase-A, which is why propranolol and MAO inhibitors change its blood levels. (Source 1)

Is it good or bad for you?

Whether it helps depends on the context. For an acute migraine attack the randomised evidence is good: pooled across 133 trials, standard-dose triptans gave two-hour headache relief in 42 to 76 percent of people and sustained pain freedom in 18 to 50 percent, with rizatriptan at the stronger end. For vestibular migraine a randomised trial found no benefit at one hour. Used too often, it becomes part of the problem: overuse on 10 or more days a month is linked to medication overuse headache, and it is contraindicated in people with ischaemic heart disease, prior stroke, peripheral vascular disease or uncontrolled hypertension. (Source 18)

How do you get more of it?

There is no way to get more of it from diet or behaviour; it exists only as a manufactured medicine. In the United States it is prescription-only, and the dose is chosen by the prescriber. In some countries the question of whether the lowest 5 mg dose should be available without a prescription has been argued in the literature, on the basis of three randomised trials in 752 patients, but that is a regulatory proposal rather than a recommendation to any reader. (Source 23)

If it is harmful, what reduces it?

The situation in which people need to reduce it is medication overuse. The literature on that is about withdrawal of the overused drug together with preventive treatment. A 2026 narrative review, which gives no effect sizes, reports that the changes in brain function appear largely reversible once withdrawal succeeds. The transient worsening of headache during withdrawal is expected and may itself need management. This is a clinical process, not something to attempt from a web page. (Source 13)

Why might someone be low in it or missing it?

Does not apply. Rizatriptan is not made by the body and is not present in food, so nobody can be deficient in it. The only sense in which someone can lack it is not having been prescribed it, or being someone for whom it is contraindicated: the label rules it out in ischaemic coronary artery disease, coronary vasospasm, prior stroke or TIA, peripheral vascular disease, ischaemic bowel disease, uncontrolled hypertension, hemiplegic or basilar migraine, recent ergot or other triptan use, and recent MAO-A inhibitor use. (Source 25)

Which whole foods contain it or feed it?

No whole food contains rizatriptan and no food feeds it. The only food-related fact in the evidence is about timing: taking it with a meal does not change how much is absorbed, but it delays the peak blood level by about an hour, which is a practical consideration for a drug meant to act fast. Separately, the orally disintegrating form contains phenylalanine. (Source 1)

What happens if you do not have it?

Nothing is missing physiologically if you never take it; the attack simply runs its own course, which for many people still resolves. The trial placebo arms show what that looks like: 22.0 percent of adolescents on placebo were pain free at two hours versus 30.6 percent on rizatriptan, and in menstrual migraine 50 to 53 percent of placebo-treated women reported two-hour pain relief. The difference the drug makes is real but partial. (Source 3)

How can you test for it?

There is no clinical test for rizatriptan status. Migraine itself is diagnosed clinically against the International Classification of Headache Disorders, and the only test of whether the drug works for a given person is whether attacks respond, measured in trials as headache relief or pain freedom at two hours. Plasma rizatriptan concentrations are measured only in pharmacokinetic research, for example the beta-blocker interaction studies, and have no role in individual care. (Source 7)

We searched: Europe PMC searches for rizatriptan plus pharmacokinetics, therapeutic drug monitoring and plasma concentration, and the full US prescribing information (sections 2, 12.3 and 14); no validated clinical test or monitoring parameter is described anywhere in that material, only research pharmacokinetics.

References

1. Organon LLC, via DailyMed (US National Library of Medicine). MAXALT (rizatriptan benzoate) - US prescribing information, Clinical Pharmacology. 2026. Read the source
2. Lancet (London, England). Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.. 2001. PMID 11728541, DOI 10.1016/s0140-6736(01)06711-3. Read the source
3. Cephalalgia : an international journal of headache. Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design.. 2012. PMID 22711898, DOI 10.1177/0333102412451358. Read the source
4. Cephalalgia : an international journal of headache. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies.. 2007. PMID 17448179, DOI 10.1111/j.1468-2982.2007.01313.x. Read the source
5. JAMA neurology. Rizatriptan vs Placebo for Attacks of Vestibular Migraine: A Randomized Clinical Trial.. 2025. PMID 40354049, DOI 10.1001/jamaneurol.2025.1006. Read the source
6. Organon LLC, via DailyMed (US National Library of Medicine). MAXALT (rizatriptan benzoate) - US prescribing information, Dosage and Administration. 2026. Read the source
7. British journal of clinical pharmacology. Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol.. 2001. PMID 11453892, DOI 10.1046/j.0306-5251.2001.01417.x. Read the source
8. Organon LLC, via DailyMed (US National Library of Medicine). MAXALT (rizatriptan benzoate) - US prescribing information, Drug Interactions. 2026. Read the source
9. JAMA neurology. Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome.. 2018. PMID 29482205, DOI 10.1001/jamaneurol.2017.5144. Read the source
10. Organon LLC, via DailyMed (US National Library of Medicine). MAXALT (rizatriptan benzoate) - US prescribing information, Metabolism and Elimination. 2026. Read the source
11. Organon LLC, via DailyMed (US National Library of Medicine). MAXALT (rizatriptan benzoate) - US prescribing information, Use in Specific Populations. 2026. Read the source
12. Organon LLC, via DailyMed (US National Library of Medicine). MAXALT (rizatriptan benzoate) - US prescribing information, Medication Overuse Headache and Serotonin Syndrome. 2026. Read the source
13. The journal of headache and pain. Breaking the medication overuse headache cycle: from nociplastic pain mechanisms to patient-centered interventions - the Junior Editorial Board vision. (narrative review). 2026. PMID 41975255, DOI 10.1186/s10194-026-02358-3. Read the source
14. Organon LLC, via DailyMed (US National Library of Medicine). MAXALT (rizatriptan benzoate) - US prescribing information, Adverse Reactions Table 1. 2026. Read the source
15. Headache. Long-term open-label safety study of rizatriptan acute treatment in pediatric migraineurs.. 2013. PMID 23078588, DOI 10.1111/j.1526-4610.2012.02285.x. Read the source
16. Pain and therapy. Lasmiditan and Different Triptans in Menstrual Migraine: A Bayesian Network Meta-analysis.. 2025. PMID 39992539, DOI 10.1007/s40122-025-00705-x. Read the source
17. Clinical toxicology (Philadelphia, Pa.). Renal infarction during the use of rizatriptan and zolmitriptan: two case reports.. 2006. PMID 16615676, DOI 10.1080/15563650500514574. Read the source
18. Headache. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.. 2015. PMID 26178694, DOI 10.1111/head.12601. Read the source
19. The journal of headache and pain. Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial.. 2007. PMID 17563841, DOI 10.1007/s10194-007-0386-7. Read the source
20. Frontiers in pharmacology. Drug interventions for acute treatment of pediatric migraine: a systematic review and network meta-analysis.. 2026. PMID 42529232, DOI 10.3389/fphar.2026.1851994. Read the source
21. Cephalalgia : an international journal of headache. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies.. 2015. PMID 25246519, DOI 10.1177/0333102414550416. Read the source
22. Organon LLC, via DailyMed (US National Library of Medicine). MAXALT (rizatriptan benzoate) tablets / MAXALT-MLT orally disintegrating tablets - US prescribing information, Warnings and Precautions. 2026. Read the source
23. Pain and therapy. Rizatriptan as an Over-the-Counter Triptan in the Treatment of Migraine Attacks.. 2024. PMID 38886287, DOI 10.1007/s40122-024-00625-2. Read the source
24. Organon LLC, via DailyMed (US National Library of Medicine). MAXALT (rizatriptan benzoate) - US prescribing information, Description. 2026. Read the source
25. Organon LLC, via DailyMed (US National Library of Medicine). MAXALT (rizatriptan benzoate) - US prescribing information, Contraindications. 2026. Read the source